Protective and anti-angiopathy effects of ginsenoside Re against diabetes mellitus via the activation of p38 MAPK, ERK1/2 and JNK signaling

Molecular Medicine Reports

Volumn 14, Issue 5, 2016, Pages 4849-4856

  Shi, Yawei ^a   Wan, Xuesi ^a   Shao, Nan ^a   Ye, Runyi ^a   Zhang, Ning ^a   Zhang, Yunjian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anti angiopathy; Diabetic angiopathy; Ginsenoside; Mitogen activated protein kinase

Indexed keywords

CHOLESTEROL; ENDOTHELIN; GINSENOSIDE RE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LIPOPROTEIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE; SUCROSE; TRIACYLGLYCEROL; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; GINSENOSIDE;

ADULT; ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOPATHY EFFECT; ARTICLE; BLOOD VESSEL INJURY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIPID DIET; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTECTION; RAT; SIGNAL TRANSDUCTION; SUGAR INTAKE; WISTAR RAT; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DRUG EFFECTS; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; GINSENOSIDES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS;

EID: 84992336085     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5821     Document Type: Article

References (48)

1. Mokini Z and Chiarelli F: The molecular basis of diabetic microangiopathy. Pediatr Endocrinol Rev 4: 138-152, 2006.
2. Whiting DR, Guariguata L, Weil C and Shaw J: IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-321, 2011.
3. Schulze MB and Hu FB Epidemiology of diabetes. In: Handbook of Epidemiology. II edition. Ahrens W and Pigeot I (eds.) Springer New York pp2429-2467, 2014.
4. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J and Nichols G: Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 293-301, 2010.
5. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH and Hu FB: Diabetes in Asia: Epidemiology, risk factors and pathophysiology. JAMA 301: 2129-2140, 2009.
6. Ramachandran A, Snehalatha C, Shetty AS and Nanditha A: Trends in prevalence of diabetes in Asian countries. World J Diabetes 3: 110-117, 2012.
7. Head J and Fuller JH: International variations in mortality among diabetic patients: The WHO multinational study of vascular disease in diabetics. Diabetologia 33: 477-481, 1990.
8. Fioretto P, Dodson PM, Ziegler D and Rosenson RS: Residual microvascular risk in diabetes: Unmet needs and future directions. Nat Rev Endocrinol 6: 19-25, 2010.
9. Shishtar E, Jovanovski E, Jenkins A and Vuksan V: Effects of Korean white ginseng (Panax Ginseng C. A. Meyer) on vascular and glycemic health in Type 2 diabetes: Results of a randomized, double blind, placebo-controlled, multiple-crossover, acute dose escalation trial. Clin Nutr Res 3: 89-97, 2014.
10. Hong YJ, Kim N, Lee K, Hee Sonn C, Eun Lee J, Tae Kim S, Ho Baeg I and Lee KM: Korean red ginseng (Panax ginseng) ameliorates type 1 diabetes and restores immune cell compartments. J Ethnopharmacol 144: 225-233, 2012.
11. Liu Z, Li W, Li X, Zhang M, Chen L, Zheng YN, Sun GZ and Ruan CC: Antidiabetic effects of malonyl ginsenosides from Panax ginseng on type 2 diabetic rats induced by high-fat diet and streptozotocin. J Ethnopharmacol 145: 233-240, 2013.
12. Sen S, Chen S, Wu Y, Feng B, Lui EK and Chakrabarti S: Preventive effects of North American ginseng (Panax quinquefolius) on diabetic retinopathy and cardiomyopathy. Phytother Res 27: 290-298, 2013.
13. Mucalo I, Jovanovski E, Vuksan V, Boẑikov V, Romi Z and Raheli D: American ginseng extract (Panax quinquefolius L.) is safe in long-term use in type 2 diabetic patients. Evid Based Complement Alternat Med 2014: 969168, 2014.
14. Jia W, Gao W and Tang L: Antidiabetic herbal drugs offi cially approved in China. Phytother Res 17: 1127-1134, 2003.
15. Yuan HD, Kim JT, Kim SH and Chung SH: Ginseng and diabetes: The evidences from in vitro, animal and human studies. J Ginseng Res 36: 27-39, 2012.
16. Committee for the Update of the Guide for the Care and Use of Laboratory Animals Guide for the Care and Use of Laboratory Animals. 6th edition. National Institutes of Health 1985
17. Vuksan V, Sung MK, Sievenpiper JL, Stavro PM, Jenkins AL, Di Buono M, Lee KS, Leiter LA, Nam KY, Arnason JT, et al: Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: Results of a randomized, double-blind, placebo-controlled study of effi cacy and safety. Nutr Metab Cardiovasc Dis 18: 46-56, 2008.
18. Baecher-Allan C and Hafl er DA: Human regulatory T cells and their role in autoimmune disease. Immunol Rev 212: 203-216, 2006.
19. Bingley PJ, Bonifacio E and Gale EA: Can we really predict IDDM? Diabetes 42: 213-220, 1993.
20. van den Oever IA, Raterman HG, Nurmohamed MT and Simsek S: Endothelial dysfunction, infl ammation, and apoptosis in diabetes mellitus. Mediators Infl amm 2010: 792393, 2010.
21. Li Y, Chen M, Xuan H and Hu F: Effects of encapsulated propolis on blood glycemic control, lipid metabolism, and insulin resistance in type 2 diabetes mellitus rats. Evid Based Complement Alternat Med 2012: 981896, 2012.
22. Haller H, Drab M and Luft FC: The role of hyperglycemia and hyperinsulinemia in the pathogenesis of diabetic angiopathy. Clin Nephrol 46: 246-255, 1996.
23. Hammes HP: Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complications 17: 16-9, 2003.
24. Kreisberg RA: Diabetic dyslipidemia. Am J Cardiol 82: 67U-73U; discussion 85U-86U, 1998.
25. Warren RE: The stepwise approach to the management of type 2 diabetes. Diabetes Res Clin Pract 65 (Suppl 1): S3-S8, 2004.
26. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 329: 977-986, 1993.
27. McGarry JD: Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18, 2002.
28. Skrha J: Pathogenesis of angiopathy in diabetes. Acta Diabetol 40 (Suppl 2): S324-S329, 2003.
29. Bardini G, Rotella CM and Giannini S: Dyslipidemia and diabetes: Reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro-and macrovascular complications. Rev Diabet Stud 9: 82-93, 2012.
30. Tilly-Kiesi M, Syvänne M, Kuusi T, Lahdenperä S and Taskinen MR: Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease. J Lipid Res 33: 333-342, 1992.
31. Stewart MW, Laker MF, Dyer RG, Game F, Mitcheson J, Winocour PH and Alberti KG: Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler Thromb 13: 1046-1052, 1993.
32. Schalkwijk CG and Stehouwer CD: Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci (Lond) 109: 143-159, 2005.
33. De Caterina R: Endothelial dysfunctions: Common denominators in vascular disease. Curr Opin Clin Nutr Metab Care 3: 453-467, 2000.
34. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY and Hebbel RP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247: 495-504, 1999.
35. Pernow J, Shemyakin A and Böhm F: New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91: 507-516, 2012.
36. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M and Rayfi eld EJ: Infl ammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99: 15596-15601, 2002.
37. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I and Shinomiya N: Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res 89: 733-740, 1998.
38. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q and Chen CJ: Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit 10: RA187-RA192, 2004.
39. Xie JT, Mehendale SR, Li X, Quigg R, Wang X, Wang CZ, Wu JA, Aung HH, A Rue P, et al: Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta 1740: 319-325, 2004.
40. Han KL, Jung MH, Sohn JH and Hwang JK: Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes. Biol Pharm Bull 29: 110-113, 2006.
41. Xie JT, Wang CZ, Wang AB, Wu J, Basila D and Yuan CS: Antihyperglycemic effects of total ginsenosides from leaves and stem of Panax ginseng. Acta Pharmacol Sin 26: 1104-1110, 2005.
42. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS and Yuan CS: Antidiabetic effects of Panax ginseng berry extract and the identifi cation of an effective component. Diabetes 51: 1851-1858, 2002.
43. Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH and Yue KK: Ginsenoside Re of Panax ginseng possesses signifi cant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 550: 173-179, 2006.
44. Park EK, Choo MK, Han MJ and Kim DH: Ginsenoside Rh1 possesses antiallergic and anti-infl ammatory activities. Int Arch Allergy Immunol 133: 113-120, 2004.
45. Zhang Z, Li X, Lv W, Yang Y, Gao H, Yang J, Shen Y and Ning G: Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol 22: 186-195, 2008.
46. Gao Y, Yang MF, Su YP, Jiang HM, You XJ, Yang YJ and Zhang HL: Ginsenoside Re reduces insulin resistance through activation of PPAR pathway and inhibition of TNF production. J Ethnopharmacol 147: 509-516, 2013.
47. Uzayisenga R, Ayeka PA and Wang Y: Anti-diabetic potential of Panax notoginseng saponins (PNS): a review. Phytother Res 28: 510-516, 2014.
48. Quan HY, Yuan HD, Jung MS, Ko SK, Park YG and Chung SH: Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. Int J Mol Med 29: 73-80, 2012.